US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

SUMMIT, N.J.--(BUSINESS WIRE) June 06, 2019 -- Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application for ozanimod for the treatment of people with...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news